To evaluate whether combination therapy increased MYCN degradation through ubiquitination and the proteasomal pathway, we treated neuroblastoma cells with combination therapy for 24 h and then added the proteasome inhibitor MG-132 (30 μM) for 4 h. Here, MYCN is linked to neuroblastoma.